Tubulin degradation: Principles, agents, and applications
Yi-Fan Zhang1, Jiao Huang1, Wei-Xin Zhang1
1School of Pharmaceutical Sciences, Institute of Drug Discovery & Development, Key Laboratory of Advanced Drug Preparation Technologies (Ministry of Education), Zhengzhou University, Zhengzhou 450001, China.
Abstract:
The microtubule system plays an important role in the mitosis and growth of eukaryotic cells, and it is considered as an appealing and highly successful molecular target for cancer treatment. In fact, microtubule targeting agents, such as paclitaxel and vinblastine, have been approved by FDA for tumor therapy, which have achieved significant therapeutic effects and sales performance. At present, microtubule targeting agents mainly include microtubule-destabilizing agents, microtubule-stabilizing agents, and a few tubulin degradation agents. Although there are few reports about tubulin degradation agents at present, tubulin degradation agents show great potential in overcoming multidrug resistance and reducing neurotoxicity. In addition, some natural drugs could specifically degrade tubulin in tumor cells, but have no effect in normal cells, thus showing a good biosafety profile. Therefore, tubulin degradation agents might exhibit a better application. Currently, some small molecules have been designed to promote tubulin degradation with potent antiproliferative activities, showing the potential for cancer treatment. In this work, we reviewed the reports on tubulin degradation, and focused on the degradation mechanism and important functional groups of chemically synthesized compounds, hoping to provide help for the degradation design of tubulin.
Insights
Tubulin degradation agents show promise for cancer treatment by targeting microtubules. This review focuses on their mechanisms and chemical design for improved cancer therapy.
Area of Science:
- Biochemistry
- Cell Biology
- Pharmacology
Background:
- Microtubules are crucial for eukaryotic cell division and growth, making them a key target in cancer therapy.
- Existing microtubule targeting agents (e.g., paclitaxel, vinblastine) are effective but face challenges like multidrug resistance and neurotoxicity.
- Tubulin degradation agents represent a novel class with potential to overcome resistance and reduce side effects.
Purpose of the Study:
- To review current research on tubulin degradation agents for cancer treatment.
- To elucidate the degradation mechanisms of tubulin-targeting compounds.
- To identify key functional groups in chemically synthesized compounds for improved degradation design.
Main Methods:
- Literature review of tubulin degradation agents.
- Analysis of degradation mechanisms.
- Examination of structure-activity relationships for synthesized compounds.
Main Results:
- Tubulin degradation agents offer a promising strategy for cancer therapy.
- Specific natural compounds can degrade tubulin in tumor cells with high biosafety.
- Small molecules promoting tubulin degradation exhibit potent antiproliferative activity.
Conclusions:
- Tubulin degradation agents have significant potential for cancer treatment, possibly overcoming limitations of current therapies.
- Understanding degradation mechanisms and chemical structures is vital for designing effective tubulin degraders.
- Further research into tubulin degradation agents could lead to novel, safer cancer therapeutics.
More Related Videos
Related Concept Videos
01:15Drugs that Stabilize Microtubules
01:10Drugs that Destabilize Microtubules
01:45Destabilization of Microtubules
02:17Microtubule Instability
02:58Regulated Protein Degradation
01:42Microtubule Associated Proteins (MAPs)